Penpulimab in combination therapy for the first-line treatment of metastatic NPC, has had its marketing application accepted by the NMPA and the FDA. Additionally, the marketing application for its ...
indicating cancer may progress earlier than previously thought. The I-SPY clinical trial platform was designed to accelerate clinical development of neoadjuvant treatments for early-stage breast ...
The study suggests a potential new drug target to stop disease progression to ... Diet Is Main Risk Factor for Colon Cancer in Younger Adults, New Study Suggests Aug. 14, 2024 — A new study has ...